CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma

Record History

1. Notable Apr 1, 2026 Primary endpoints: 2 to 1 Enrollment target: 36 to 40 · Eligibility criteria shortened, about 34 words · Secondary endpoints: 7 to 5 · 2 morev3 Show 5 more changesShow less

   • Enrollment target: 36 to 40
   • Eligibility criteria shortened, about 34 words
   • Secondary endpoints: 7 to 5
   • Study description shortened, about 1 word
   • Study title expanded, about 3 words

   See this version in full on ClinicalTrials.gov ↗

2. Notable Dec 12, 2023 Phase: Early Phase 1 to Phase 2 Trial status: Not Yet Recruiting to Recruiting · Primary completion date: Dec 20, 2023 to Dec 20, 2026 · Start date changed from estimate of Dec 20, 2020 to Dec 3, 2020 · 4 morev2 Show 7 more changesShow less

   • Trial status: Not Yet Recruiting to Recruiting
   • Primary completion date: Dec 20, 2023 to Dec 20, 2026
   • Start date changed from estimate of Dec 20, 2020 to Dec 3, 2020
   • Eligibility criteria expanded, about 9 words
   • Site details revised
   • Study description shortened, about 1 word
   • Study title shortened, about 1 word

   See this version in full on ClinicalTrials.gov ↗

3. Minor Dec 3, 2020 Study First Submitted

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.